Top

Published in:

01-12-2011 | Original Article

Leptin is an independent determinant of bone mineral density in men with type 2 diabetes mellitus

Authors: Olga Vasilkova, Tatiana Mokhort, Tamara Sharshakova, Naomi Hayashida, Noboru Takamura

Published in: Acta Diabetologica | Issue 4/2011

Abstract

To investigate the possible relationship of leptin to bone mineral density (BMD) in men with type 2 diabetes mellitus (T2DM), we screened 168 Belarusian men aged 45–65 years. Plasma total cholesterol (TC), high-density lipoprotein cholesterol, and triglyceride concentrations were assessed, and low-density lipoprotein cholesterol and very low-density lipoprotein cholesterol (LDL-C) were calculated. Hemoglobin A_1c, immune-reactive insulin (IRI), serum total testosterone, and sex hormone-binding globulin were also evaluated. BMD was evaluated using dual-energy X-ray absorptiometry. By univariate linear regression analysis, BMD was significantly correlated with body mass index (r = 0.23, P = 0.002) and leptin (r = 0.21, P = 0.006). By multivariate regression analysis adjusting for confounding factors, log leptin was independently correlated with BMD (β = 0.058, P = 0.001). Our study revealed that leptin is an independent determinant of BMD in patients with T2DM. Further research is necessary to confirm this association and to develop ways to correct abnormalities of bone metabolism in patients with T2DM.

Vestergaard P, Rejnmark L, Mosekilde L (2005) Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk. Diabetologia 48:1292–1299PubMedCrossRef

Isaia G, Bodrato L, Carlevatto V, Mussetta M, Salamano G, Molinatti GM (1987) Osteoporosis in type II diabetes. Acta Diabetol Lat 24:305–310PubMedCrossRef

Gregorio F, Cristallini S, Santeusanio F, Filipponi P, Fumelli P (1994) Osteopenia associated with non-insulin-dependent diabetes mellitus: what are the causes? Diabetes Res Clin Pract 23:43–54PubMedCrossRef

Tuominen JT, Impivaara O, Puukka P, Rönnemaa T (1999) Bone mineral density in patients with type 1 and type 2 diabetes. Diabetes Care 22:1196–1200PubMedCrossRef

Barrett-Connor E, Holbrook TL (1992) Sex differences in osteoporosis in older adults with non-insulin-dependent diabetes mellitus. JAMA 16:3333–3337CrossRef

Yamauchi M, Sugimoto T, Yamaguchi T, Nakaoka D, Kanzawa M, Yano S, Ozuru R, Sugishita T, Chihara K (2001) Plasma leptin concentrations are associated with bone mineral density and the presence of vertebral fractures in postmenopausal women. Clin Endocrinol 55:341–347CrossRef

Steppan CM, Crawford DT, Chidsey-Frink KL, Ke H, Swick AG (2000) Leptin is a potent stimulator of bone growth in ob/ob mice. Regul Pept 92:73–78PubMedCrossRef

Ducy P, Amling M, Takeda S, Priemel M, Schilling AF, Beil FT, Shen J, Vinson C, Rueger JM, Karsenty G (2000) Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 100:197–207PubMedCrossRef

Kontogianni M, Dafni U, Routsias J, Skopouli F (2004) Blood leptin and adiponectin as possible mediators of the relation between fat mass and BMD in perimenopausal women. J Bone Miner Res 19:546–551PubMedCrossRef

10.

Abou Samra R, Baba N, Torbay N, Dib L, Fuleihan GE (2005) High plasma leptin is not associated with higher bone mineral density in insulin-resistant premenopausal obese women. J Clin Endocrinol Metab 90:2588–2594PubMedCrossRef

11.

Kassem HS, Arabi A, Zantout MS, Azar ST (2008) Negative effect of leptin on bone mass in type 1 diabetes. Acta Diabetol 45:237–241PubMedCrossRef

12.

Nar A, Gedik O (2009) The effect of metformin on leptin in obese patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease. Acta Diabetol 46:113–118PubMedCrossRef

13.

Watanabe S, Takeuchi Y, Fukumoto S, Fujita H, Nakano T, Fujita T (2003) Decrease in serum leptin by troglitazone is associated with preventing bone loss in type 2 diabetic patients. J Bone Miner Metab 21:166–171PubMedCrossRef

14.

Anon (1993) Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 94:646–650CrossRef

15.

Safaei H, Janghorbani M, Aminorroaya A, Amini M (2007) Lovastatin effects on bone mineral density in postmenopausal women with type 2 diabetes mellitus. Acta Diabetol 44:76–82PubMedCrossRef

16.

Barrett-Connor E, Kritz-Silverstein D (1996) Does hyperinsulinemia preserve bone? Diabetes Care 19:1388–1392PubMedCrossRef

17.

Rondinone CM (2006) Adipocyte-derived hormones, cytokines, and mediators. Endocrine 29:81–90PubMedCrossRef

18.

Friedman JM, Halaas JL (1998) Leptin and the regulation of body weight in mammals. Nature 395:763–770PubMedCrossRef

19.

Park JS, Cho MH, Nam JS, Ahn CW, Cha BS, Lee EJ, Lim SK, Kim KR, Lee HC (2010) Visceral adiposity and leptin are independently associated with C-reactive protein in Korean type 2 diabetic patients. Acta Diabetol 47:113–118PubMedCrossRef

20.

Thomas T, Gori F, Khosla S, Jensen MD, Burguera B, Riggs BL (1999) Leptin acts on human marrow stromal cells to enhance differentiation to osteoblasts and to inhibit differentiation to adipocytes. Endocrinology 140:1630–1638PubMedCrossRef

21.

Reid IR (2008) Relationships between fat and bone. Osteoporos Int 19:595–606PubMedCrossRef

22.

Singh DK, Winocour P, Summerhayes B, Viljoen A, Gand Sivakumar, Farrington K (2010) Low serum osteoprotegerin levels in normoalbuminuric type 1 diabetes mellitus. Acta Diabetol 47(Suppl 1):105–110PubMedCrossRef

23.

Schoppet M, Preissner KT, Hofbauer LC (2002) RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vasc Biol 22:549–553PubMedCrossRef

24.

Thomas T, Burguera B, Melton LJ III, Atkinson EJ, O’Fallon WM, Riggs BL, Khosla S (2001) Role of serum leptin, insulin, and estrogen levels as potential mediators of the relationship between fat mass and bone mineral density in men versus women. Bone 29:114–120PubMedCrossRef

25.

Morberg CM, Tetens I, Black E, Toubro S, Soerensen TI, Pedersen O, Astrup A (2003) Leptin and bone mineral density: a cross-sectional study in obese and nonobese men. J Clin Endocrinol Metab 88:5795–5800PubMedCrossRef

26.

Sun AJ, Jing T, Heymsfield SB, Phillips GB (2003) Relationship of leptin and sex hormones to bone mineral density in men. Acta Diabetol 40:101–105CrossRef

27.

Sato M, Takeda N, Sarui H, Takami R, Takami K, Hayashi M, Sasaki A, Kawachi S, Yoshino K, Yasuda K (2001) Association between serum leptin concentrations and bone mineral density, and biochemical markers of bone turnover in adult men. J Clin Endocrinol Metab 86:5273–5276PubMedCrossRef

28.

Ruhl CE, Everhart JE (2002) Relationship of serum leptin concentration with bone mineral density in the United States population. J Bone Miner Res 17:1896–1903PubMedCrossRef

29.

Dennison EM, Syddall HE, Fall CH, Javaid MK, Arden NK, Phillips DI, Cooper C (2004) Plasma leptin concentration and change in bone density among elderly men and women: the hertfordshire cohort study. Calcif Tissue Int 74:401–406PubMedCrossRef

30.

Zoico E, Zamboni M, Adami S, Vettor R, Mazzali G, Tosoni P, Bissoli L, Bosello O (2003) Relationship between leptin levels and bone mineral density in the elderly. Clin Endocrinol (Oxf) 59:97–103CrossRef

31.

Oh KW, Lee WY, Rhee EJ, Baek KH, Yoon KH, Kang MI, Yun EJ, Park CY, Ihm SH, Choi MG, Yoo HJ, Park SW (2005) The relationship between serum resistin, leptin, adiponectin, ghrelin levels and bone mineral density in middle-aged men. Clin Endocrinol (Oxf) 63:131–138CrossRef

32.

Pasco JA, Henry MJ, Kotowicz MA, Collier GR, Ball MJ, Ugoni AM, Nicholson GC (2001) Serum leptin levels are associated with bone mass in nonobese women. J Clin Endocrinol Metab 86:1884–1887PubMedCrossRef

33.

Blain H, Vuillemin A, Guillemin F, Durant R, Hanesse B, de Talance N, Doucet B, Jeandel C (2002) Serum leptin level is a predictor of bone mineral density in postmenopausal women. J Clin Endocrinol Metab 87:1030–1035PubMedCrossRef

34.

Roux C, Arabi A, Porcher R, Garnero P (2003) Serum leptin as a determinant of bone resorption in healthy postmenopausal women. Bone 33:847–852PubMedCrossRef

35.

Iwamoto I, Douchi T, Kosha S, Murakami M, Fujino T, Nagata Y (2000) Relationships between serum leptin level and regional bone mineral density, bone metabolic markers in healthy women. Acta Obstet Gynecol Scand 79:1060–1064PubMed

36.

Martini G, Valenti R, Giovani S, Franci B, Campagna S, Nuti R (2001) Influence of insulin-like growth factor-1 and leptin on bone mass in healthy postmenopausal women. Bone 28:113–117PubMedCrossRef

37.

38.

Goulding A, Taylor RW (1998) Plasma leptin values in relation to bone mass and density and to dynamic biochemical markers of bone resorption and formation in postmenopausal women. Calcif Tissue Int 63:456–458PubMedCrossRef

39.

Blum M, Harris SS, Must A, Naumova EN, Phillips SM, Rand WM, Dawson-Hughes B (2003) Leptin, body composition and bone mineral density in premenopausal women. Calcif Tissue Int 73:27–32PubMedCrossRef

40.

Thomas T, Burguera B (2002) Is leptin the link between fat and bone mass? J Bone Miner Res 17:1563–1569PubMedCrossRef

41.

Dennison E, Yoshimura N, Hashimoto T, Cooper C (1998) Bone loss in Great Britain and Japan: a comparative longitudinal study. Bone 23:379–382PubMedCrossRef

42.

Weiss LA, Barrett-Connor E, von Mühlen D, Clark P (2006) Leptin predicts BMD and bone resorption in older women but not older men: the Rancho Bernardo study. J Bone Miner Res 21:758–764PubMedCrossRef

43.

Esteghamati A, Khalilzadeh O, Ashraf H, Zandieh A, Morteza A, Rashidi A, Meysamie A, Nakhjavani M (2010) Physical activity is correlated with serum leptin independent of obesity: results of the national surveillance of risk factors of noncommunicable diseases in Iran (SuRFNCD-2007). Metabolism 59:1730–1735PubMedCrossRef

44.

Iacone R, Russo O, Russo P, Venezia A, Varriale V, Gerardi MC, Strazzullo P (2002) Plasma leptin measurements in epidemiological investigation: comparison of two commonly used assays and estimate of regression dilution bias. Nutr Metab Cardiovasc Dis 12:71–79PubMed

Title: Leptin is an independent determinant of bone mineral density in men with type 2 diabetes mellitus
Authors: Olga Vasilkova
Tatiana Mokhort
Tamara Sharshakova
Naomi Hayashida
Noboru Takamura
Publication date: 01-12-2011
Publisher: Springer Milan
Published in: Acta Diabetologica / Issue 4/2011
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI: https://doi.org/10.1007/s00592-011-0266-0

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2011

The effects of rosiglitazone and metformin on inflammation and endothelial dysfunction in patients with type 2 diabetes mellitus

Effect of pioglitazone on cardiac sympathovagal modulation in patients with type 2 diabetes

Sugar-sweetened and diet beverage consumption is associated with cardiovascular risk factor profile in youth with type 1 diabetes

Long-term predictive power of simple function tests for cardiovascular autonomic neuropathy in diabetes: a population-based study

Iatrogenic diabetes mellitus during ACTH therapy in an infant with West syndrome

HBV and HCV infection in type 2 diabetes mellitus: a survey in three diabetes units in different Italian areas

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials